Krystal Biotech (NASDAQ:KRYS) Stock Rating Upgraded by Chardan Capital

Krystal Biotech (NASDAQ:KRYS) was upgraded by Chardan Capital to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Other analysts have also recently issued research reports about the stock. HC Wainwright boosted their price target on shares of Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research note on Tuesday, June 16th. Citigroup raised their price objective on Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research report on Tuesday. Evercore reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. Jefferies Financial Group reiterated a “buy” rating and issued a $474.00 target price on shares of Krystal Biotech in a research report on Monday, July 13th. Finally, Bank of America increased their price target on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $361.56.

Krystal Biotech Stock Performance

KRYS stock opened at $325.78 on Monday. Krystal Biotech has a one year low of $132.31 and a one year high of $382.54. The company’s fifty day moving average price is $340.79 and its 200-day moving average price is $297.13. The company has a market capitalization of $9.64 billion, a PE ratio of 40.82 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The firm had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. On average, research analysts predict that Krystal Biotech will post 7.27 EPS for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the transaction, the executive vice president directly owned 1,000 shares of the company’s stock, valued at $347,270. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the sale, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 26,642 shares of company stock worth $8,243,923. 13.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KRYS. Handelsbanken Fonder AB increased its stake in Krystal Biotech by 58.4% during the fourth quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock worth $26,084,000 after acquiring an additional 39,000 shares during the last quarter. Fisher Asset Management LLC bought a new stake in shares of Krystal Biotech in the 4th quarter valued at approximately $933,000. Biondo Investment Advisors LLC boosted its holdings in shares of Krystal Biotech by 31.3% in the 4th quarter. Biondo Investment Advisors LLC now owns 68,130 shares of the company’s stock worth $16,797,000 after purchasing an additional 16,245 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Krystal Biotech by 15.6% in the 4th quarter. Principal Financial Group Inc. now owns 165,074 shares of the company’s stock worth $40,697,000 after purchasing an additional 22,231 shares during the period. Finally, William Blair Investment Management LLC increased its position in shares of Krystal Biotech by 152.1% during the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock valued at $92,783,000 after purchasing an additional 227,038 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.